ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017
|
|
- Adam Tate
- 5 years ago
- Views:
Transcription
1 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone 30 mg tablet alogliptin 12.5 mg-pioglitazone 45 mg tablet alogliptin 25 mg tablet alogliptin 25 mg-pioglitazone 15 mg tablet alogliptin 25 mg-pioglitazone 30 mg tablet alogliptin 25 mg-pioglitazone 45 mg tablet alogliptin 6.25 mg tablet Kazano 12.5 mg-1,000 mg tablet Kazano 12.5 mg-500 mg tablet Nesina 12.5 mg tablet Nesina 25 mg tablet Nesina 6.25 mg tablet Oseni 12.5 mg-15 mg tablet Oseni 12.5 mg-30 mg tablet Oseni 12.5 mg-45 mg tablet Oseni 25 mg-15 mg tablet Oseni 25 mg-30 mg tablet Oseni 25 mg-45 mg tablet COVERAGE OF ALOGLIPTIN CONTAINING PRODUCTS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF EITHER A SAXAGLIPTIN OR SITAGLIPTIN PRODUCT. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 1
2 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME ANTI-EMETIC MEDICATIONS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF GENERIC ONDANSETRON AND GENERIC GRANISETRON. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED. 2
3 ARB STEP Edarbi 40 mg tablet Edarbi 80 mg tablet Edarbyclor 40 mg-12.5 mg tablet Edarbyclor 40 mg-25 mg tablet COVERAGE OF CERTAIN BRANDED ARBS AND ARB COMBOS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF TWO GENERIC ARB OR ARB COMBINATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 3
4 BRAND HMG STEP Altoprev 20 mg tablet,extended release Altoprev 40 mg tablet,extended release Altoprev 60 mg tablet,extended release Vytorin 10 mg-10 mg tablet Vytorin 10 mg-20 mg tablet Vytorin 10 mg-40 mg tablet Vytorin 10 mg-80 mg tablet COVERAGE OF BRAND NAME STATINS (HMGS) REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF TWO GENERIC STATIN MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 4
5 BRAND TOPICAL ANTIFUNGALS STEP Ertaczo 2 % topical cream Exelderm 1 % topical cream Exelderm 1 % topical solution Luzu 1 % topical cream Mentax 1 % topical cream Naftin 1 % topical gel Naftin 2 % topical gel Oxistat 1 % lotion COVERAGE OF BRAND NAME TOPICAL ANTIFUNGALS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE TO TWO GENERIC TOPICAL ANTIFUNGAL MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED. 5
6 BRAND TOPICAL STEROIDS STEP Ala-Scalp 2 % lotion Capex 0.01 % shampoo Cordran Tape Large Roll 4 mcg/cm2 Desonate 0.05 % topical gel Enstilar % % topical foam Halog 0.1 % topical cream Halog 0.1 % topical ointment Kenalog mg/gram topical aerosol Locoid 0.1 % lotion Pandel 0.1 % topical cream Taclonex % % topical ointment Taclonex % % topical suspension Topicort 0.25 % topical spray COVERAGE OF BRAND NAME TOPICAL STEROIDS REQUIRES DOCUMENTATION OF A TRIAL OF AT LEAST TWO DIFFERENT GENERIC TOPICAL STEROID MEDICATIONS. IF THERE LACKS TWO DIFFERENT GENERIC TOPICAL STEROID MEDICATIONS INDICATED TO TREAT A SPECIFIC DIAGNOSIS, THEN A TRIAL OF ONE GENERIC TOPICAL STEROID MEDICATION SATISFIES THIS REQUIREMENT. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 6
7 CAMBIA POWDER STEP Cambia 50 mg oral powder packet COVERAGE OF CAMBIA POWDER PACKETS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ONE NON-STEROIDAL ANTI- INFLAMMATORY DRUG (SUCH AS IBUPROFEN OR NAPROXEN) AND ONE TRIPTAN DRUG (SUCH AS SUMATRIPTAN OR RIZATRIPTAN). IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 7
8 COREG CR STEP Coreg CR 10 mg capsule, extended release Coreg CR 20 mg capsule, extended release Coreg CR 40 mg capsule, extended release Coreg CR 80 mg capsule, extended release COVERAGE OF COREG CR REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF GENERIC CARVEDILOL. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 8
9 CUPRIMINE Cuprimine 250 mg capsule COVERAGE OF CUPRIMINE REQUIRES DOCUMENTATION OF PRIOR USE OF DEPEN. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 9
10 FENTANYL TRANSDERMAL PATCH Duragesic 100 mcg/hr transdermal patch Duragesic 12 mcg/hr transdermal patch Duragesic 25 mcg/hr transdermal patch Duragesic 50 mcg/hr transdermal patch Duragesic 75 mcg/hr transdermal patch fentanyl 100 mcg/hr transdermal patch fentanyl 12 mcg/hr transdermal patch fentanyl 25 mcg/hr transdermal patch fentanyl 37.5 mcg/hour transdermal patch fentanyl 50 mcg/hr transdermal patch fentanyl 62.5 mcg/hour transdermal patch fentanyl 75 mcg/hr transdermal patch fentanyl 87.5 mcg/hour transdermal patch DUE TO SAFETY CONCERNS REGARDING THE USE OF FENTANYL PATCHES IN PATIENTS WITHOUT PRIOR OPIATE USE, COVERAGE OF FENTANYL PATCH REQUIRES DOCUMENTATION OF PRIOR USE OF ONE OPIATE ANALGESIC (SUCH AS HYDROCODONE/APAP, OXYCODONE, MORPHINE) DURING THE PREVIOUS 60 DAYS. IF A REQUIRED DRUG APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 60 DAYS, THEN 10
11 INVEGA Invega Sustenna 117 mg/0.75 ml intramuscular syringe Invega Sustenna 156 mg/ml intramuscular syringe Invega Sustenna 234 mg/1.5 ml intramuscular syringe Invega Sustenna 39 mg/0.25 ml intramuscular syringe Invega Sustenna 78 mg/0.5 ml intramuscular syringe Invega Trinza 273 mg/0.875 ml intramuscular syringe Invega Trinza 410 mg/1.315 ml intramuscular syringe Invega Trinza 546 mg/1.75 ml intramuscular syringe Invega Trinza 819 mg/2.625 ml intramuscular syringe COVERAGE OF INVEGA REQUIRES DOCUMENTATION OF A TRIAL OF RISPERIDONE AND AT LEAST ONE OTHER ANTIPSYCHOTIC MEDICATION OR MOOD STABILIZER. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED. 11
12 ONMEL Onmel 200 mg tablet COVERAGE OF ONMEL REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL ITRACONAZOLE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 12
13 PHOSPHATE BINDERS Auryxia 210 mg iron tablet Fosrenol 1,000 mg chewable tablet Fosrenol 1,000 mg oral powder packet Fosrenol 500 mg chewable tablet Fosrenol 750 mg chewable tablet Fosrenol 750 mg oral powder packet COVERAGE OF CERTAIN PHOSPHATE BINDERS REQUIRES DOCUMENTATION OF PRIOR USE OF SEVELAMER TABLETS, SEVELAMER PACKETS, RENVELA TABLETS, OR RENVELA PACKETS. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 13
14 SAVELLA STEP Savella 100 mg tablet Savella 12.5 mg (5)-25 mg(8)-50mg(42) tablets in a dose pack Savella 12.5 mg tablet Savella 25 mg tablet Savella 50 mg tablet COVERAGE OF SAVELLA REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL DULOXETINE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 14
15 SOOLANTRA Soolantra 1 % topical cream COVERAGE OF SOOLANTRA REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE TO ONE GENERIC TOPICAL METRONIDAZOLE PRODUCT. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED. 15
16 SPORANOX Sporanox 10 mg/ml oral solution Sporanox 100 mg capsule COVERAGE OF SPORANOX REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL ITRACONAZOLE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN AS ORAL ITRACONAZOLE CAPSULES ARE NOT FDA-APPROVED FOR TREATMENT OF OROPHARYNGEAL AND ESOPHAGHEAL CANDIDIASIS, THE COVERAGE OF SPORANOX ORAL SOLUTION WILL BE COVERED FOR THESE DIAGNOSES WITHOUT THE STEP THERAPY REQUIREMENT. 16
17 TRIPTAN INJECTABLE STEP Sumavel DosePro 4 mg/0.5 ml subcutaneous needle-free injector Sumavel DosePro 6 mg/0.5 ml subcutaneous needle-free injector Zembrace Symtouch 3 mg/0.5 ml subcutaneous pen injector COVERAGE OF CERTAIN BRAND NAME INJECTABLE TRIPTAN MEDICATIONS REQUIRES DOCUMENTATION OF A TRIAL OF GENERIC SUMATRIPTAN INJECTABLE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED. 17
18 TRIPTAN STEP Relpax 20 mg tablet Relpax 40 mg tablet Treximet 10 mg-60 mg tablet Treximet 85 mg-500 mg tablet COVERAGE OF CERTAIN BRAND NAME TRIPTAN MEDICATIONS REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF TWO GENERIC TRIPTAN MEDICATIONS. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 18
19 ULORIC STEP Uloric 40 mg tablet Uloric 80 mg tablet COVERAGE OF ULORIC REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF GENERIC ALLOPURINOL. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 19
20 VFEND Vfend 200 mg tablet Vfend 200 mg/5 ml (40 mg/ml) oral suspension Vfend 50 mg tablet COVERAGE OF VFEND REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL VORICONAZOLE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN ADDITIONAL DOCUMENTATION IS NOT REQUIRED 20
21 XADAGO Xadago 100 mg tablet Xadago 50 mg tablet COVERAGE OF XADAGO REQUIRES A TRIAL OF ORAL SELEGILINE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 21
22 ZELAPAR STEP Zelapar 1.25 mg disintegrating tablet COVERAGE OF ZELAPAR REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL SELEGILINE. IF THE REQUIRED DRUG APPEARS IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 22
23 ZYFLO, ZYFLO CR zileuton ER 600 mg tablet,extended release 12hr mphase Zyflo 600 mg tablet Zyflo CR 600 mg tablet,extended release COVERAGE OF ZYFLO, ZYFLO CR, OR ZILEUTON ER REQUIRES DOCUMENTATION OF SIGNIFICANT INTOLERANCE OR THERAPEUTIC FAILURE OF ORAL MONTELUKAST AND ZAFIRLUKAST. IF THE REQUIRED DRUGS APPEAR IN THE PRESCRIPTION PROFILE IN THE LAST 365 DAYS, THEN 23
24 Index A Ala-Scalp 2 % lotion... 6 alogliptin 12.5 mg tablet... 1 alogliptin 12.5 mg-metformin 1,000 mg tablet... 1 alogliptin 12.5 mg-metformin 500 mg tablet... 1 alogliptin 12.5 mg-pioglitazone 15 mg tablet... 1 alogliptin 12.5 mg-pioglitazone 30 mg tablet... 1 alogliptin 12.5 mg-pioglitazone 45 mg tablet... 1 alogliptin 25 mg tablet... 1 alogliptin 25 mg-pioglitazone 15 mg tablet 1 alogliptin 25 mg-pioglitazone 30 mg tablet 1 alogliptin 25 mg-pioglitazone 45 mg tablet 1 alogliptin 6.25 mg tablet... 1 Altoprev 20 mg tablet,extended release... 4 Altoprev 40 mg tablet,extended release... 4 Altoprev 60 mg tablet,extended release... 4 Auryxia 210 mg iron tablet C Cambia 50 mg oral powder packet... 7 Capex 0.01 % shampoo... 6 Cordran Tape Large Roll 4 mcg/cm Coreg CR 10 mg capsule, extended release 8 Coreg CR 20 mg capsule, extended release 8 Coreg CR 40 mg capsule, extended release 8 Coreg CR 80 mg capsule, extended release 8 Cuprimine 250 mg capsule... 9 D Desonate 0.05 % topical gel... 6 Duragesic 100 mcg/hr transdermal patch. 10 Duragesic 12 mcg/hr transdermal patch Duragesic 25 mcg/hr transdermal patch Duragesic 50 mcg/hr transdermal patch Duragesic 75 mcg/hr transdermal patch E Edarbi 40 mg tablet... 3 Edarbi 80 mg tablet... 3 Edarbyclor 40 mg-12.5 mg tablet... 3 Edarbyclor 40 mg-25 mg tablet... 3 Enstilar % % topical foam... 6 Ertaczo 2 % topical cream... 5 Exelderm 1 % topical cream... 5 Exelderm 1 % topical solution... 5 F fentanyl 100 mcg/hr transdermal patch fentanyl 12 mcg/hr transdermal patch fentanyl 25 mcg/hr transdermal patch fentanyl 37.5 mcg/hour transdermal patch 10 fentanyl 50 mcg/hr transdermal patch fentanyl 62.5 mcg/hour transdermal patch 10 fentanyl 75 mcg/hr transdermal patch fentanyl 87.5 mcg/hour transdermal patch 10 Fosrenol 1,000 mg chewable tablet Fosrenol 1,000 mg oral powder packet Fosrenol 500 mg chewable tablet Fosrenol 750 mg chewable tablet Fosrenol 750 mg oral powder packet H Halog 0.1 % topical cream... 6 Halog 0.1 % topical ointment... 6 I Invega Sustenna 117 mg/0.75 ml intramuscular syringe Invega Sustenna 156 mg/ml intramuscular syringe Invega Sustenna 234 mg/1.5 ml intramuscular syringe Invega Sustenna 39 mg/0.25 ml intramuscular syringe Invega Sustenna 78 mg/0.5 ml intramuscular syringe Invega Trinza 273 mg/0.875 ml intramuscular syringe Invega Trinza 410 mg/1.315 ml intramuscular syringe Invega Trinza 546 mg/1.75 ml intramuscular syringe Invega Trinza 819 mg/2.625 ml intramuscular syringe K Kazano 12.5 mg-1,000 mg tablet... 1 Kazano 12.5 mg-500 mg tablet... 1 Kenalog mg/gram topical aerosol... 6 L Locoid 0.1 % lotion... 6 Luzu 1 % topical cream
25 M Mentax 1 % topical cream... 5 N Naftin 1 % topical gel... 5 Naftin 2 % topical gel... 5 Nesina 12.5 mg tablet... 1 Nesina 25 mg tablet... 1 Nesina 6.25 mg tablet... 1 O Onmel 200 mg tablet Oseni 12.5 mg-15 mg tablet... 1 Oseni 12.5 mg-30 mg tablet... 1 Oseni 12.5 mg-45 mg tablet... 1 Oseni 25 mg-15 mg tablet... 1 Oseni 25 mg-30 mg tablet... 1 Oseni 25 mg-45 mg tablet... 1 Oxistat 1 % lotion... 5 P Pandel 0.1 % topical cream... 6 R Relpax 20 mg tablet Relpax 40 mg tablet S Sancuso 3.1 mg/24 hour transdermal patch 2 Savella 100 mg tablet Savella 12.5 mg (5)-25 mg(8)-50mg(42) tablets in a dose pack Savella 12.5 mg tablet Savella 25 mg tablet Savella 50 mg tablet Soolantra 1 % topical cream Sporanox 10 mg/ml oral solution Sporanox 100 mg capsule Sumavel DosePro 4 mg/0.5 ml subcutaneous needle-free injector Sumavel DosePro 6 mg/0.5 ml subcutaneous needle-free injector T Taclonex % % topical ointment... 6 Taclonex % % topical suspension... 6 Topicort 0.25 % topical spray... 6 Treximet 10 mg-60 mg tablet Treximet 85 mg-500 mg tablet U Uloric 40 mg tablet Uloric 80 mg tablet V Vfend 200 mg tablet Vfend 200 mg/5 ml (40 mg/ml) oral suspension Vfend 50 mg tablet Vytorin 10 mg-10 mg tablet... 4 Vytorin 10 mg-20 mg tablet... 4 Vytorin 10 mg-40 mg tablet... 4 Vytorin 10 mg-80 mg tablet... 4 X Xadago 100 mg tablet Xadago 50 mg tablet Z Zelapar 1.25 mg disintegrating tablet Zembrace Symtouch 3 mg/0.5 ml subcutaneous pen injector zileuton ER 600 mg tablet,extended release 12hr mphase Zuplenz 4 mg oral soluble film... 2 Zuplenz 8 mg oral soluble film... 2 Zyflo 600 mg tablet Zyflo CR 600 mg tablet,extended release
ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018
Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
More informationALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018
Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
More informationANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019
Step Therapy Requirements Effective April 1, 2019 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME
More informationAcyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
More informationJANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.
ANTI DIABETICS BYDUREON 2 MG SUBCUTANEOUS JANUVIA 25 MG TABLET EXTENDED RELEASE SUSPENSION JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationALPHA GLUCOSIDASE INHIBITOR THERAPY
ALPHA GLUCOSIDASE INHIBITOR THERAPY GLYSET Step 1: One generic formulary product containing one of the following ingredients: glimeperide, glipizide, metformin or pioglitazone. Step 2: Glyset PAGE 1 LAST
More informationStep Therapy Group. Atypical Antipsychotic Agents
Atypical Antipsychotic Agents Any beneficiary newly enrolled into Community Care, Inc. currently receiving aripiprazole, aripiprazole ODT, risperidone, risperidone ODT, olanzapine, olanzapine ODT, quetiapine,
More informationStep Therapy Medications
Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,
More informationNeighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
More informationYour prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More information2016 Step Therapy (ST) Criteria
2016 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that
More informationBYSTOLIC. Products Affected Step 2: BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET. Details BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET
BYSTOLIC BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET authorization for a Step 2 drug may be given. Step 1 Drug(s): generic beta-blockers and/or combinations,
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationHEALTH SHARE/PROVIDENCE (OHP)
HEALTH SHARE/PROVIDENCE (OHP) STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, HealthNow New York Inc. requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
More informationStep Therapy Criteria
Tier 5 Formulary Step Therapy 2016 Updated: 05/24/2016 Effective: 06/01/2016 What is Step Therapy? Some prescription drugs require step therapy (ST). In some cases, the plan requires you to first try certain
More informationTriptan Quantity Limit
*- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5
More information5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
More informationANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
More information5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details
5-ASA DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum. 1 ANTIEMETICS
More information5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release
Updated 11/1/17 5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda
More information2018 Medicare Part D Formulary Change
2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy
More informationALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal
ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12
More information2015 Step Therapy (ST) Criteria
2015 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that
More informationY0133_StepTherapyCriteria _C 10/18/18 Y0133_StepTherapyCriteria _C es 10/18/18
Step Therapy Grid Certain cost-effective drugs must be used before other more expensive drugs are covered. For example, certain brand-name medications will only be covered if a generic alternative has
More informationANTICONVULSANT THERAPY
Network Health Insurance Corporation NetworkCares Step Therapy Last Updated: 7/2017 ANTICONVULSANT THERAPY Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200
More information**CRITERIA UNDER CMS REVIEW**
**CRITERIA UNDER CMS REVIEW** ANTICONVULSANTS APTIOM TABLET 200 MG APTIOM TABLET 400 MG APTIOM TABLET 600 MG APTIOM TABLET 800 MG BANZEL SUSPENSION 40 MG/ML BANZEL TABLET 200 MG BANZEL TABLET 400 MG BRIVIACT
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationMichigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500
More information2018 Step Therapy FID 18088
2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG,
More informationALLERGIC CONJUNCTIVITIS AGENTS
2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops
More informationCRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
More informationMercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
More informationMedicare Part D Drugs that Require Step Therapy Effective 12/01/2017
Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017 Providers may call the Pharmacy Help Desk at 800-641-8921 for more information or questions about criteria. The formulary may change
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueCross BlueShield of WNY requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationClinical Policy: Sumatriptan Reference Number: CP.CPA.260 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.260 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationADHD STIMULANTS - SCORE
ADHD STIMULANTS - SCORE Step Therapy Strattera Patient needs to have a paid claim for two generic formulary ADHD stimulant medications. Formulary ID# 00017034 Last Updated: 08/01/2017 1 ALPHA GLUCOSIDASE
More informationANTICONVULSANT STEP THERAPY
2019 First Choice VIP Care Plus Formulary Document: 2019 Step Therapy Formulary ID: 19391 Last Updated: 2/2019 Effective Date: 03-01-2019 ANTICONVULSANT STEP THERAPY APTIOM 200 MG APTIOM 400 MG APTIOM
More informationATYPICAL ANTIPSYCHOTICS
Step Therapy CareOregon 2018 Last Updated: 07/27/2018 ATYPICAL ANTIPSYCHOTICS Fanapt Fanapt Titration Pack Paliperidone Er Vraylar The following criteria applies to members who newly start on the drug:
More information2016 PRESCRIPTION DRUG LIST UPDATES
2016 PRESCRIPTION DRUG LIST UPDATES Evergreen Health 1 st Quarter Below are key updates to the four-tier EHB Prescription Formulary, effective January 1, 2016. Please consult the full formulary for more
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationAGGRENOX. Products Affected. Details. GRP B2 Last Updated: 09/01/2018. Aggrenox
GRP B2 Last Updated: 09/01/2018 AGGRENOX Aggrenox A documented trial of one month of formulary generic aspirin/dipyridamole capsules. NR_0009_3742 09/2014 Formulary ID: 18066: version 15 1 ANTICONVULSANTS
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: The formulary changes listed in the table below were reviewed and approved at our second quarter 2018, Pharmacy and Therapeutics Committee
More informationMercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
More information2018 Step Therapy Criteria (List of Step Therapy Criteria)
Criteria Last Updated: October 05, 2017 Effective Date: January 1, 2018 2018 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP DUALCHOICE CAL MEDICONNECT PLAN (MEDICARE-
More informationDT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
More informationAPREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE
APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50
More informationUPDATE Ohana QUEST Integration Medicaid
UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes
More informationButrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butrans Page: 1 of 9 Last Review Date: September 15, 2017 Butrans (buprenorphine patch) Description
More informationADHD STIMULANTS - SCORE
Step Therapy Trillium 5 Tier Effective Date: 12/01/2017 Approval Date: 10/24/2017 ADHD STIMULANTS - SCORE Strattera Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant
More informationANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019
Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
More informationYou ll find the most up-to-date comprehensive version of our formulary on our website, Click on Drug Finder.
3/1/2018 Medicare Part D Formulary Change In an effort to cover the most needed, cost-effective prescriptions, the AlohaCare Advantage Plus (HMO SNP) Formulary is updated monthly. The following are drugs
More informationSimply Step Therapy Document September 2018 Y0114_18_33074_I_009
2018 2018 Simply Step Therapy Document September 2018 Aptiom APTIOM 200 MG TABLET APTIOM 400 MG TABLET Y0114_18_33074_I_009 APTIOM 600 MG TABLET APTIOM 800 MG TABLET Criteria If the patient has tried a
More informationOXYCODONE IR (oxycodone)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Oxycodone hydrochloride, a pure opioid agonist, is used in the treatment of moderate to severe pain (1-2). The precise mechanism of action is unknown; however,
More informationLevorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
More informationDPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet
DPP4 INHIBITORS Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet Januvia 50 mg tablet Onglyza 2.5 mg tablet Onglyza 5 mg tablet Tradjenta 5 mg tablet
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More informationEmblem Medicaid 3Q18 Formulary Updates
ALKERAN 2 MG TABLET Removed from Formulary 7/9/2018 AMITIZA 24 MCG CAPSULES Removed from Formulary 7/9/2018 AMITIZA 8 MCG CAPSULE Removed from Formulary 7/9/2018 avo cream topical emulsion Removed from
More informationPartners Notice of Change March 2017
New Added Products: Effective 3/1/2017 Drug Reason Tier Restrictions abacavir 600 mg-lamivudine 300 QL ADRENACLICK 0.15 MG/0.15 ML INJECTION,AUTO- INJECTOR ADRENACLICK 0.3 MG/0.3 ML INJECTION, AUTO- INJECTOR
More informationUPDATE WellCare s New Jersey
UPDATE WellCare s New Jersey Preferred Drug List July 13, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes will be
More informationNetwork Health Insurance Corporation Upcoming Negative Changes to the Medicare Part D Formulary
Requesting an Exception to the Formulary You can ask Network Health Insurance Corporation to make an exception to our coverage rules. Generally, we will only approve your request for an exception if alternative
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION
More informationHysingla ER. Hysingla ER (hydrocodone bitartrate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.38 Subject: Hysingla ER Page: 1 of 9 Last Review Date: September 15, 2017 Hysingla ER Description
More information